Loading...
01/11 11:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed mixed signals. The company reported strong revenue growth and secured significant milestone payments, indicating positive financial performance. However, rising R&D costs and net losses are concerning. The Q&A section highlighted operational challenges and competitive pressures but also showed promising clinical data and potential partnerships. Overall, the sentiment is neutral due to the balance of positive revenue growth and financial challenges, along with the cautious tone in the Q&A section.
Revenue GBP25.4 million (up GBP7.9 million or 45%) year-over-year, driven by advancements in partner programs, including a $10 million option fee from AstraZeneca and $4 million in milestones from Hansoh.
R&D Costs GBP44 million (up GBP8.4 million or 24%) year-over-year, primarily due to advancing the proprietary zerlasiran and divesiran programs.
General and Administrative Costs GBP20.6 million (up GBP1 million or 5%) year-over-year, mainly due to non-cash share-based expenses related to employee share options.
Net Loss GBP43.3 million (up GBP2.8 million or 7%) year-over-year, attributed to increased R&D expenses from advancing clinical programs.
Cash and Cash Equivalents GBP54 million (approximately $68.8 million) at the end of December 2023, with a significant increase to over $200 million in early 2024 due to a $120 million PIPE financing and additional $20 million raised in January 2024.
Zerlasiran Phase 2 Data: Positive top line Phase 2 data for zerlasiran in patients with high Lp(a)(a) reported, showing significant Lp(a) reductions of 90% or greater at week 36.
Divesiran Clinical Progress: Ongoing Phase 1 study of divesiran for polycythemia vera shows promising emerging data, with results expected by June 2024.
Market Expansion with AstraZeneca: Entered the clinic with the first product candidate under AstraZeneca collaboration, triggering a $10 million milestone payment.
Revenue Growth: Revenue increased to GBP25.4 million in 2023 from GBP17.5 million in 2022, driven by advancements in partner programs.
Cash Position: Cash and cash equivalents increased to approximately $200 million in early 2024, extending runway into 2026.
Focus on Proprietary Pipeline: Commitment to advancing and expanding proprietary pipeline, including two complement assets and several undisclosed programs.
Market Challenges: 2023 was a challenging year in the broader market, indicating potential competitive pressures and economic factors affecting the company's performance.
Regulatory Risks: The company is navigating the complexities of clinical development and regulatory approvals, which can impact timelines and success rates.
Supply Chain Challenges: The ongoing collaborations and advancements in clinical programs may face supply chain challenges that could affect the timely delivery of products.
Financial Risks: The company reported a net loss of GBP43.3 million in 2023, indicating financial strain that could impact future investments and operational capabilities.
Collaboration Risks: Mallinckrodt's decision to not pursue further development of SLN501 may affect future revenue streams and partnerships.
Clinical Development Risks: The success of the ongoing clinical trials for zerlasiran and divesiran is uncertain, and any adverse results could significantly impact the company's prospects.
2024 Key Strategic Priorities: Focus on proprietary clinical programs, particularly zerlasiran for high Lp(a)(a) and divesiran for polycythemia vera (PV). Phase 3 planning for zerlasiran is underway.
Partnerships and Collaborations: Entered the clinic with the first product candidate under AstraZeneca collaboration, triggering a $10 million milestone payment.
Pipeline Expansion: Commitment to advancing and expanding proprietary pipeline, including two complement assets and undisclosed targets with Hansoh.
Financial Position: Strong balance sheet following $120 million PIPE financing completed in February.
Revenue Expectations: Revenue for 2023 was GBP25.4 million, up from GBP17.5 million in 2022, driven by partner program advancements.
Cash Runway: Cash balance increased to over $200 million in early 2024, extending runway into 2026.
Future Milestones: Anticipate achieving additional milestones as collaborations advance, including $10 million already achieved in early 2024.
Clinical Data Reporting: Expect to report 48-week data for zerlasiran in Q2 2024 and PV data for divesiran by June 2024.
Share Buyback Program: None
Dividend Program: None
The earnings call highlights financial challenges, such as a net operating loss and dependency on securing a partner for Phase 3 studies, which could delay progress. Despite increased revenue, the company's financial health remains precarious with significant R&D expenses. The Q&A section reveals management's reluctance to provide clarity on partnerships, raising concerns about execution risks. These factors, combined with competitive market pressures and supply chain challenges, suggest a negative sentiment towards the stock's short-term performance.
The earnings call reveals moderate revenue growth and improved net loss, but lacks strong catalysts like new partnerships or guidance upgrades. Management's vague responses in the Q&A and uncertainties around partnerships and competition present potential risks. The decision to delay the Phase 3 trial until a partner is secured extends the cash runway, but doesn't provide immediate positive impact. Overall, the mixed signals and lack of decisive positive news suggest a neutral sentiment for the stock price over the next two weeks.
The earnings call revealed mixed signals. The company reported strong revenue growth and secured significant milestone payments, indicating positive financial performance. However, rising R&D costs and net losses are concerning. The Q&A section highlighted operational challenges and competitive pressures but also showed promising clinical data and potential partnerships. Overall, the sentiment is neutral due to the balance of positive revenue growth and financial challenges, along with the cautious tone in the Q&A section.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
